The effect of intracameral dexamethasone used at the end of cataract surgery on macular edema in eyes with diabetic retinopathy

Year 2019, , 18 - 23, 25.01.2019

Tevfik Oğurel , Kemal Örnek Reyhan Oğurel Zafer Onaran

https://doi.org/10.32322/jhsm.491881

Cited By: 1

Abstract

Aim:
To evaluate the effect of intracameral dexamethasone
on diabetic macular edema injected at the end of cataract surgery in patients
with diabetic retinopathy.

Material
and Method: Thirty patients with diabetic retinopathy and
cataract were included in this study. All patients underwent a complete
ophthalmic examination which consisted best-corrected visual acuity (BCVA),
anterior segment evaluation with slit lamp microscopy, fundus examination with Goldman
three mirror lens,  intraocular pressure (IOP)
measurement with applanation tonometry before cataract surgery. Fundus fluorescein angiography (FFA) was taken
following each ocular examination. At the end of cataract surgery 0,1 cc
dexamethasone was given intracamerally from the cataract incision. Each patient
was reevaluated with BCVA, IOP and FFA at 1^st month after surgery.

Results:
Thirty one eye of 18 (%64.3) women and 10 (%35.7) mans who ages ranging from 52
to 87 were enrolled in this study. All of patients had type 2 diabetes. Mean
age of the patients was 65.25±8.57 and 16 (%25.8) eyes had diffuse diabetic
macular edema, 8 (%25.8) eyes had cystoid macular edema and 7 (%22.6)
eyes had both diffuse diabetic macular edema and cystoid
diabetic macular edema. Macular edema did not change in 19 (%61.3) eyes and decreased in 12 (%38.7) eyes. The
mean corrected visual acuity was preoperatively 0.10±0.11, postoperatively 0.2±0.22
at first month. Postoperative increase in vısual acuity was found
statistically significant (p˂0,001).

Conclusion: Intracameral
dexamethasone injection appears to be effective in reducing the effect of
surgery on diabetic macular edema in eyes with diabetic retinopathy and
cataract

Keywords

Dexamethasone, macular edema, cataract, diabetic retinopathy

Diyabetik retinopatili gözlerde katarakt ameliyatı sonunda ön kamaraya deksametazon verilmesinin makula ödemi üzerine etkisi

Abstract

Amaç: Diyabetik retinopati (DR)’li
hastalarda katarakt ameliyatı sonunda ön kamaraya verilen deksametazonun maküla
ödemi (MÖ) üzerine muhtemel etkilerinin araştırılması amaçlanmıştır.

Gereç
ve Yöntem:
Çalışmaya DR’li ve makula ödemi olan 28 katarakt hastası dahil edildi. Bütün
hastalara katarakt operasyonu öncesinde en iyi düzeltilmiş görme keskinlikleri (EDGK),
biyomikroskopik ön segment değerlendirmesi, Goldmann üç aynalı lensi ile fundus
muayeneleri ve Goldmann aplanasyon tonometresi ile göz içi basınç (GİB)
ölçümlerinden oluşan oftalmolojik muayenenin ardından, maküla ödeminin
değerlendirilmesi amacıyla fundus floresein anjiyografi (FFA) çekildi. Katarakt
operasyonunun sonunda hastalara kesi yerinden 0,1 cc deksametazon verildi.
Hastalar birinci ay sonunda EDGK, GİB ve FFA ile değerlendirildi.

Bulgular: Çalışmaya yaşları 52-87 arasında
değişen ve diyabetik makula ödemi (DMÖ) olan 18 (%64,3) kadın ile 10 (%35,7)
erkek hastanın 31 gözü dahil edildi. Hastaların tamamında tip 2 diyabet mevcuttu.
Olguların ortalama yaşı 65,25±8,57 olup
gözlerden 16 (%25,8)’ sında diffüz, 8 (%25,8)’ inde kistoid, 7 (%22,6)’ sinde
hem diffüz hem de kistoid makula ödemi (KMÖ) mevcuttu. 19
(%61,3) hastada  postoperatif makula
ödeminde herhangi bir değişiklik gözlenmezken 12 (%38,7) hastada maküler ödemde
 azalma söz konusuydu (p=0,201). Operasyon öncesi en iyi düzeltilmiş görme keskinliği
0,10±0,11 olup, operasyon sonrası 1.ay görme keskinliği 0,2±0,22
düzeylerindeydi. Bu artış istatistiksel olarak anlamlıydı (p˂0.001).

Sonuç:
DMÖ ve kataraktı
olan gözlerde, katarakt ameliyatı sonunda ön kamaraya deksametazon
uygulamasının, cerrahi işlemin MÖ üzerine olan olumsuz etkisini azalttığı
görülmektedir. 

Keywords

Deksametazon, makula ödemi, katarakt, diyabetik retinopati

References

• 1. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetik Retinopati. IV. Diabetic macular edema. Ophthalmology 1984; 91:1464-74.
• 2. Moss SE, Klein R, Klein BEK. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105:998-1003.
• 3. Bresnick GH. Diabetic macular edema. Ophthalmology 1986; 93:989-97.
• 4. Bayraktar MZ, Ergin MM, Or M, Subaşı M, Menteş J, özkan SS, Müftüğlu G, Akar S. Diyabetik Makulopati ve Tedavisi. Diyabetik retinopati. özkan Ş,Akar S. İstanbul. Dilek Ofset. 2000:23-36.
• 5. Fong DS, Ferris FL, Davis MD. ETDRS Report no 24. Causes of severe visual loss in the early treatment diabetic retinopathy study. Am J Ophthalmol 1999; 127:137-161.
• 6. Ünal M, Akman A, Yaylalı V, Sönmez M, Acar S. Diffüz diabetik makula ödeminde lazer fotokoagülasyon ve asetazolamid etkinliğinin karşılaştırılması. T Oft Gaz 1999; 29: 421-425.
• 7. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594-1602.
• 8. Mittra R A, Borrillo J L, Dev S et al 2000 Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Archives of Ophthalmology 118: 912–917
• 9. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT. Vitrectomy for diffuse diabetic macular edema associated with a premacular posterior hyaloid. Am J Ophthalmol 2000;130: 178-186.
• 10. McCuen BW II, Besler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91:785-88.
• 11. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008 Aug;31(8):1541-6.)
• 12. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005656.
• 13. Jaffe GJ, Burton TC. Progression of nonproliferative diabetic retinopathy following cataract extraction. Arch Ophthalmol 1988; 106:745-749.
• 14. Sebestyen JG. Intraocular lenses and diabetes mellitus. Am J Ophthalmol 1986; 101:425-428.
• 15. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. Br J Ophthalmol. 1996;80789-93.
• 16. Karalezli A, Borazan M, A.Akova Y. Intracameral triamcinolone acetonide to control postoperative inflamasyon following cataract surgery with phacoemulsificastion. Acta Ophthalmol. 2008; 86:183-187.
• 17. Diane TW Chang, et al. Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma. Clinical Ophthalmology 2009 ; 3: 345- 355.
• 18. Kwak HW,D’Amico DJ.Evaluation of the retinal toxicitiy and pharmacokinetics of dexamethasone after intravitreal injection.Arch Ophthalmol,1992;110(2);259-266
• 19. Morgan CM,Schatz H,Vine AK,et al.Ocular complicatıons associated with retrobulbar injections.Ophthalmology.1988;95(5):835-837
• 20. Giles CL. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol.1974;77(4):438-441.
• 21. Akduman L, Olk RJ. Diode laser (810 nm) versus argon green (514nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1997; 104:1433-1441.